Inside Celltrion: a biosimilar success story built on landfill
By Dan Stanton
- Last updated on
GMT
Biopharma-Reporter visited the 'pioneers of the mAb biosimilar industry'
Ambition, hard work and a focus on quality has made Celltrion the ‘pioneers of the mAb biosimilar industry,’ the firm told Biopharma-Reporter during a tour of its biomanufacturing site in Songdo, Korea.
The clinical value of biologics for the treatment of many disease indications has been accompanied by phenomenal sales. By 2026, the global market for...
